Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Mahrukh M, Syeda"'
Autor:
ANNE DAVIDSON, Naomi I Maria, David Polsky, Weijia Zhang, Betsy J Barnes, Chirag Raparia, Julien Papoin, Zeguo Sun, Rachel Josselsohn, Ailing Lu, Hani Katerji, Mahrukh M Syeda, Robert Paulson, Theodosia Kalfa, Lionel Blanc
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss Suppl 2 (2024)
Externí odkaz:
https://doaj.org/article/5a2543ee58094c4eb75344259c8f9167
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0133615 (2015)
Peripheral ischemia, resulting from diminished arterial flow and defective local vascularization, is one of the main causes of impaired wound healing in diabetes. Vasodilatory prostaglandins (PGs), including PGE2 and PGI2, regulate blood flow in peri
Externí odkaz:
https://doaj.org/article/4c23e3b14924432bb95be8d8fb87ee86
Autor:
Broderick Corless, David Polsky, Yongzhao Shao, Iman Osman, Mahrukh M. Syeda, Gregory Chang, Samantha Cooper, George Karlin-Neumann
Publikováno v:
The Journal of Molecular Diagnostics. 21:274-285
Detecting mutations in the plasma of patients with solid tumors is becoming a valuable method of diagnosing and monitoring cancer. The TERT promoter is mutated at high frequencies in multiple cancer types, most commonly at positions -124 and -146 (de
Autor:
Harry Ostrer, Mahrukh M. Syeda, Johnny Loke, Yongzhao Shao, Kinnari Upadhyay, Susan Klugman, Alexander Pearlman
Publikováno v:
Genetics in Medicine. 19:1071-1077
Identifying women at high risk for breast cancer can trigger a personal program of annual mammograms and magnetic resonance imaging scans for early detection, prophylactic surgery, or chemoprevention to reduce the risk of cancer. Yet, current strateg
Autor:
Gregory Chang, Nathaniel H. Fleming, Yongzhao Shao, Cindy Spittle, Farbod Darvishian, Russell S. Berman, Iman Osman, Mahrukh M. Syeda, George Karlin-Neumann, Anna C. Pavlick, Richard L. Shapiro, Jyothirmayee S. Tadepalli, Shria Blake, Jennifer M. Wiggins, Broderick Corless, David Polsky
Publikováno v:
The Journal of investigative dermatology. 140(8)
Mutational heterogeneity can contribute to therapeutic resistance in solid cancers. In melanoma, the frequencies of intertumoral and intratumoral heterogeneity are controversial. We examined mutational heterogeneity within individual patients with me
Autor:
Mahrukh M, Syeda, Jennifer M, Wiggins, Broderick, Corless, Cindy, Spittle, George, Karlin-Neumann, David, Polsky
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2055
The detection of cell-free, circulating tumor DNA (ctDNA) in the blood of patients with solid tumors is often referred to as "liquid biopsy." ctDNA is particularly attractive as a candidate biomarker in the blood. It is relatively stable after blood
Autor:
Broderick Corless, Mahrukh M. Syeda, David Polsky, Cindy Spittle, Jennifer M. Wiggins, George Karlin-Neumann
Publikováno v:
Biomarkers for Immunotherapy of Cancer ISBN: 9781493997725
The detection of cell-free, circulating tumor DNA (ctDNA) in the blood of patients with solid tumors is often referred to as "liquid biopsy." ctDNA is particularly attractive as a candidate biomarker in the blood. It is relatively stable after blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e580935cc149d7efbab0c607074f56ec
https://doi.org/10.1007/978-1-4939-9773-2_7
https://doi.org/10.1007/978-1-4939-9773-2_7
Autor:
Georgina V. Long, Paul Nathan, Mahrukh M. Syeda, David Polsky, Michael A. Davies, Eduard Gasal, Dirk Schadendorf, Jean-Jacques Grob, Mahtab Marker, Keith T. Flaherty, Caroline Robert, Antoni Ribas, Jan C. Brase, Matthew Squires, Jennifer M. Wiggins, Broderick Corless
9510 Background: There are no validated blood-based biomarkers to monitor efficacy in pts with advanced melanoma. Lactate dehydrogenase (LDH) is an established prognostic factor; however, it is not normally used to inform treatment decisions. ctDNA a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b86e39c367b57f167b9e41cff430785
Autor:
Jean-Jacques Grob, Mahrukh M. Syeda, Antoni Ribas, Georgina V. Long, Mahtab Marker, Broderick Corless, Dirk Schadendorf, Keith T. Flaherty, James Garrett, David Polsky, Eduard Gasal, Matthew Squires, Caroline Robert, Jan C. Brase, Jennifer M. Wiggins, Michael A. Davies, Paul Nathan
Publikováno v:
Lancet Oncol
The Lancet. Oncology, vol 22, iss 3
The Lancet. Oncology, vol 22, iss 3
BackgroundMelanoma lacks validated blood-based biomarkers for monitoring and predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising biomarker; however, various detection methods have been used, and, to date, no large s
Autor:
David Polsky, Iman Osman, Mahrukh M. Syeda, Cindy Spittle, Broderick Corless, George Karlin-Neumann
Publikováno v:
Clinical Cancer Research. 26:A66-A66
Introduction: Serial monitoring of sensitive and specific blood-based biomarkers of disease burden in cancer patients could enable clinicians to adjust treatments at the earliest signs of disease progression when the likelihood of improved outcomes i